Evidence map›Paper›PMID 26608110›Full record

ReviewMethods (San Diego, Calif.)2016

High-throughput imaging: Focusing in on drug discovery in 3D.

Linfeng Li, Qiong Zhou, Ty C Voss, Kevin L Quick, Daniel V LaBarbera

Abstract readReview
In one paragraph

Review in Methods (San Diego, Calif.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Expert reviews in molecular medicine · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Linfeng LiDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Qiong ZhouDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Ty C VossPerkinElmer Inc., 940 Winter Street, Waltham, MA 02451, United States.
Kevin L QuickPerkinElmer Inc., 940 Winter Street, Waltham, MA 02451, United States.
Daniel V LaBarberaDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States; The University of Colorado Cancer Center, Developmental Therapeutics Program, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States. Electronic address: Daniel.LaBarbera@ucdenver.edu.

Funding

Novel Therapeutics Against Diabetic Eye DiseaseR01EY021498 · NEI · UNIVERSITY OF COLORADO DENVER · PI LABARBERA, DANIEL V., PETRASH, JONATHAN MARK · 2011 to 2015
$2.1M
NEI NIH HHS R01 EY021498NEI NIH HHS R01EY021498
6 · The paper itself

Abstract

3D organotypic culture models such as organoids and multicellular tumor spheroids (MCTS) are becoming more widely used for drug discovery and toxicology screening. As a result, 3D culture technologies adapted for high-throughput screening formats are prevalent. While a multitude of assays have been reported and validated for high-throughput imaging (HTI) and high-content screening (HCS) for novel drug discovery and toxicology, limited HTI/HCS with large compound libraries have been reported. Nonetheless, 3D HTI instrumentation technology is advancing and this technology is now on the verge of allowing for 3D HCS of thousands of samples. This review focuses on the state-of-the-art high-throughput imaging systems, including hardware and software, and recent literature examples of 3D organotypic culture models employing this technology for drug discovery and toxicology screening.

Indexed as

Drug Screening Assays, AntitumorAntineoplastic AgentsCell Line, TumorCell SurvivalDrug DiscoveryHepatocytesHumansImage Processing, Computer-AssistedImaging, Three-DimensionalSmall Molecule LibrariesSoftwareSpheroids, CellularAntineoplastic AgentsSmall Molecule Libraries3D image analysis software3D tissue cultureHigh-content screeningHigh-throughput imagingMulticellular tumor spheroidsOrganoids

Identifiers

PMID26608110
PMCPMC4766031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.